Clinical Trial Update: Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer [NA]

View source ↗

Summary

A completed bioequivalence study comparing IG-001 to nab-paclitaxel in metastatic or locally recurrent breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Locally Recurrent Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• IG-001

Snippet

Sponsor: Sorrento Therapeutics, Inc. | Conditions: Metastatic Breast Cancer, Locally Recurrent Breast Cancer | NA | Status: COMPLETED